Barbital

Identification

Name

Barbital

Accession Number

DB01483

Type

Small Molecule

Groups

Illicit

Description

A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB01483 (Barbital)

×

Close

Synonyms

Not Available

Categories

• Anticholinergic Agents
• Anticonvulsants
• Barbiturates
• Barbiturates, Plain
• Central Nervous System Agents
• Central Nervous System Depressants
• Cytochrome P-450 CYP2C19 Inducers
• Cytochrome P-450 CYP2C19 Substrates
• Cytochrome P-450 CYP3A Inducers
• Cytochrome P-450 CYP3A4 Inducers
• Cytochrome P-450 Enzyme Inducers
• GABA Agents
• GABA Modulators
• Hypnotics and Sedatives
• Nervous System
• Neurotransmitter Agents
• Nicotinic Antagonists
• Psycholeptics
• Pyrimidines
• Pyrimidinones

UNII

5WZ53ENE2P

CAS number

57-44-3

Weight

Average: 184.1925
Monoisotopic: 184.08479226

Chemical Formula

C₈H₁₂N₂O₃

InChI Key

FTOAOBMCPZCFFF-UHFFFAOYSA-N

InChI

InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)

IUPAC Name

5,5-diethyl-1,3-diazinane-2,4,6-trione

SMILES

CCC1(CC)C(=O)NC(=O)NC1=O

Pharmacology

Indication

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Target	Actions	Organism
AGamma-aminobutyric acid receptor subunit alpha-1	potentiator	Human
AGamma-aminobutyric acid receptor subunit alpha-2	potentiator	Human
AGamma-aminobutyric acid receptor subunit alpha-3	potentiator	Human
AGamma-aminobutyric acid receptor subunit alpha-4	potentiator	Human
AGamma-aminobutyric acid receptor subunit alpha-5	potentiator	Human
AGamma-aminobutyric acid receptor subunit alpha-6	potentiator	Human
UNeuronal acetylcholine receptor subunit alpha-4	antagonist	Human
UNeuronal acetylcholine receptor subunit alpha-7	antagonist	Human
UGlutamate receptor 2	antagonist	Human
UGlutamate receptor ionotropic, kainate 2	antagonist	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when Barbital is combined with 7-Nitroindazole.	Experimental
Acebutolol	The serum concentration of Acebutolol can be decreased when it is combined with Barbital.	Approved, Investigational
Acenocoumarol	The metabolism of Acenocoumarol can be increased when combined with Barbital.	Approved, Investigational
Acepromazine	The risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine.	Approved
Acetaminophen	The metabolism of Acetaminophen can be increased when combined with Barbital.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Barbital is combined with Adipiplon.	Investigational
Agmatine	The metabolism of Agmatine can be increased when combined with Barbital.	Experimental, Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine.	Approved, Investigational
Alaproclate	The risk or severity of adverse effects can be increased when Barbital is combined with Alaproclate.	Experimental
Aldesleukin	Barbital may increase the hypotensive activities of Aldesleukin.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Barbital is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Barbital.	Approved, Illicit
Aliskiren	Barbital may increase the hypotensive activities of Aliskiren.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Barbital is combined with Allopregnanolone.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Barbital is combined with Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Barbital is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital.	Approved, Illicit, Investigational
Alprenolol	The serum concentration of Alprenolol can be decreased when it is combined with Barbital.	Approved, Withdrawn
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Barbital.	Experimental, Investigational
Amifostine	Barbital may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amikacin	The risk or severity of adverse effects can be increased when Barbital is combined with Amikacin.	Approved, Investigational, Vet Approved
Amiloride	Barbital may increase the hypotensive activities of Amiloride.	Approved
Amineptine	The metabolism of Amineptine can be increased when combined with Barbital.	Illicit, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Barbital.	Approved
Amiodarone	Barbital may increase the hypotensive activities of Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be increased when combined with Barbital.	Approved
Amitriptylinoxide	The metabolism of Amitriptylinoxide can be increased when combined with Barbital.	Approved, Investigational
Amlodipine	Barbital may increase the hypotensive activities of Amlodipine.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital.	Approved, Illicit
Amoxapine	The metabolism of Amoxapine can be increased when combined with Barbital.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Barbital is combined with Amperozide.	Experimental
Amphotericin B	Barbital may increase the hypotensive activities of Amphotericin B.	Approved, Investigational
Amrinone	The metabolism of Amrinone can be increased when combined with Barbital.	Approved
Amyl Nitrite	Barbital may increase the hypotensive activities of Amyl Nitrite.	Approved
Apomorphine	Barbital may increase the hypotensive activities of Apomorphine.	Approved, Investigational
Apraclonidine	Barbital may increase the hypotensive activities of Apraclonidine.	Approved
Aranidipine	The metabolism of Aranidipine can be increased when combined with Barbital.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.	Approved, Investigational
Arotinolol	The serum concentration of Arotinolol can be decreased when it is combined with Barbital.	Investigational
Arsenic trioxide	Barbital may increase the hypotensive activities of Arsenic trioxide.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Barbital is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Asenapine is combined with Barbital.	Approved
Atenolol	The serum concentration of Atenolol can be decreased when it is combined with Barbital.	Approved
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Barbital.	Approved, Vet Approved
Azaperone	The risk or severity of adverse effects can be increased when Barbital is combined with Azaperone.	Investigational, Vet Approved
Azelastine	Barbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelnidipine	The metabolism of Azelnidipine can be increased when combined with Barbital.	Approved, Investigational
Azilsartan medoxomil	Barbital may increase the hypotensive activities of Azilsartan medoxomil.	Approved, Investigational
Azimilide	The metabolism of Azimilide can be increased when combined with Barbital.	Investigational
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Barbital.	Approved
Barnidipine	Barbital may increase the hypotensive activities of Barnidipine.	Approved
Befunolol	The serum concentration of Befunolol can be decreased when it is combined with Barbital.	Experimental
Benazepril	Barbital may increase the hypotensive activities of Benazepril.	Approved, Investigational
Bencyclane	The metabolism of Bencyclane can be increased when combined with Barbital.	Experimental
Bendroflumethiazide	Barbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.	Approved
Benidipine	The metabolism of Benidipine can be increased when combined with Barbital.	Approved, Investigational
Benperidol	The risk or severity of adverse effects can be increased when Barbital is combined with Benperidol.	Approved, Investigational
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Barbital.	Approved
Benzphetamine	The risk or severity of adverse effects can be increased when Barbital is combined with Benzphetamine.	Approved, Illicit
Benzthiazide	Barbital may increase the orthostatic hypotensive activities of Benzthiazide.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Barbital is combined with Benzyl alcohol.	Approved
Bepridil	Barbital may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betaxolol	The serum concentration of Betaxolol can be decreased when it is combined with Barbital.	Approved, Investigational
Bevantolol	The serum concentration of Bevantolol can be decreased when it is combined with Barbital.	Approved
Bioallethrin	The metabolism of Bioallethrin can be increased when combined with Barbital.	Approved, Experimental
Bisoprolol	The serum concentration of Bisoprolol can be decreased when it is combined with Barbital.	Approved
Bopindolol	The serum concentration of Bopindolol can be decreased when it is combined with Barbital.	Approved
Bortezomib	Barbital may increase the hypotensive activities of Bortezomib.	Approved, Investigational
Bretylium	Barbital may increase the hypotensive activities of Bretylium.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Barbital.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Barbital.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Barbital is combined with Bromisoval.	Experimental
Bromocriptine	Barbital may increase the hypotensive activities of Bromocriptine.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Barbital is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Brompheniramine is combined with Barbital.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Barbital is combined with Brotizolam.	Approved, Investigational, Withdrawn
Bucindolol	The serum concentration of Bucindolol can be decreased when it is combined with Barbital.	Investigational
Bufuralol	The serum concentration of Bufuralol can be decreased when it is combined with Barbital.	Experimental, Investigational
Bumetanide	Barbital may increase the hypotensive activities of Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital.	Approved, Investigational
Bupranolol	The serum concentration of Bupranolol can be decreased when it is combined with Barbital.	Approved
Buprenorphine	Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The risk or severity of adverse effects can be increased when Barbital is combined with Bupropion.	Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Barbital is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Barbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Barbital is combined with Butamben.	Approved, Withdrawn
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Barbital.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital.	Approved, Illicit, Vet Approved
Butriptyline	The metabolism of Butriptyline can be increased when combined with Barbital.	Approved
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Barbital.	Approved
Canagliflozin	Barbital may increase the hypotensive activities of Canagliflozin.	Approved
Candesartan cilexetil	Barbital may increase the hypotensive activities of Candesartan cilexetil.	Approved
Canertinib	The risk or severity of adverse effects can be increased when Barbital is combined with Canertinib.	Investigational
Captopril	Barbital may increase the hypotensive activities of Captopril.	Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital.	Approved, Investigational
Carbetocin	Barbital may increase the hypotensive activities of Carbetocin.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Barbital.	Approved
Carboxyamidotriazole	The metabolism of Carboxyamidotriazole can be increased when combined with Barbital.	Investigational
Carfentanil	The risk or severity of adverse effects can be increased when Barbital is combined with Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Barbital.	Approved
Caroverine	The metabolism of Caroverine can be increased when combined with Barbital.	Experimental
Carteolol	The serum concentration of Carteolol can be decreased when it is combined with Barbital.	Approved
Carvedilol	Barbital may increase the hypotensive activities of Carvedilol.	Approved, Investigational
Celiprolol	The serum concentration of Celiprolol can be decreased when it is combined with Barbital.	Approved, Investigational
Cetirizine	The risk or severity of adverse effects can be increased when Cetirizine is combined with Barbital.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chloramphenicol	The metabolism of Barbital can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbital.	Approved, Illicit, Investigational
Chlormadinone	The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Barbital.	Experimental
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Barbital.	Approved, Investigational, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital.	Approved
Chlorothiazide	Barbital may increase the orthostatic hypotensive activities of Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbital.	Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.	Approved, Investigational, Withdrawn
Chlorthalidone	Barbital may increase the orthostatic hypotensive activities of Chlorthalidone.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Barbital.	Approved
Cilazapril	Barbital may increase the hypotensive activities of Cilazapril.	Approved
Cilnidipine	Barbital may increase the hypotensive activities of Cilnidipine.	Approved, Investigational
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital.	Approved, Vet Approved
Cinnarizine	The metabolism of Cinnarizine can be increased when combined with Barbital.	Approved, Investigational
Citalopram	The risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Clemastine is combined with Barbital.	Approved, Investigational
Clevidipine	Barbital may increase the hypotensive activities of Clevidipine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Clidinium is combined with Barbital.	Approved
Clindamycin	The risk or severity of adverse effects can be increased when Barbital is combined with Clindamycin.	Approved, Vet Approved
Clobazam	The risk or severity of adverse effects can be increased when Clobazam is combined with Barbital.	Approved, Illicit
Clofarabine	Barbital may increase the hypotensive activities of Clofarabine.	Approved, Investigational
clomethiazole	The risk or severity of adverse effects can be increased when Barbital is combined with clomethiazole.	Investigational
Clomipramine	The metabolism of Clomipramine can be increased when combined with Barbital.	Approved, Investigational, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Clonazepam is combined with Barbital.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Barbital.	Approved
Clopenthixol	The risk or severity of adverse effects can be increased when Barbital is combined with Clopenthixol.	Experimental
Cloranolol	The serum concentration of Cloranolol can be decreased when it is combined with Barbital.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.	Approved, Illicit
Clorindione	The metabolism of Clorindione can be increased when combined with Barbital.	Experimental
Clothiapine	The risk or severity of adverse effects can be increased when Barbital is combined with Clothiapine.	Experimental
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Barbital.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Barbital.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Barbital.	Approved, Illicit
Conivaptan	Barbital may increase the hypotensive activities of Conivaptan.	Approved, Investigational
Cyclandelate	The metabolism of Cyclandelate can be increased when combined with Barbital.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Cyclizine is combined with Barbital.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be increased when combined with Barbital.	Approved
Cyclopenthiazide	Barbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.	Experimental
Cyclopropane	The risk or severity of adverse effects can be increased when Barbital is combined with Cyclopropane.	Experimental
Cyclosporine	The metabolism of Cyclosporine can be increased when combined with Barbital.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Barbital.	Approved
Cyproterone acetate	The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Barbital.	Approved, Investigational
Dantrolene	The risk or severity of adverse effects can be increased when Dantrolene is combined with Barbital.	Approved, Investigational
Dapagliflozin	Barbital may increase the hypotensive activities of Dapagliflozin.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine.	Investigational
Darodipine	The metabolism of Darodipine can be increased when combined with Barbital.	Experimental
Deramciclane	The risk or severity of adverse effects can be increased when Barbital is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Barbital.	Approved
Desipramine	The metabolism of Desipramine can be increased when combined with Barbital.	Approved, Investigational
Desloratadine	The risk or severity of adverse effects can be increased when Desloratadine is combined with Barbital.	Approved, Investigational
Desogestrel	The therapeutic efficacy of Desogestrel can be decreased when used in combination with Barbital.	Approved
Desvenlafaxine	The risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Barbital is combined with Detomidine.	Vet Approved
Deutetrabenazine	The risk or severity of sedation and somnolence can be increased when Barbital is combined with Deutetrabenazine.	Approved, Investigational
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbital.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital.	Approved, Vet Approved
Dexniguldipine	The metabolism of Dexniguldipine can be increased when combined with Barbital.	Experimental
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Barbital.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital.	Approved, Illicit, Investigational, Withdrawn
Dexverapamil	The metabolism of Dexverapamil can be increased when combined with Barbital.	Experimental
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Barbital.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Barbital.	Approved, Illicit, Investigational, Vet Approved
Dibenzepin	The metabolism of Dibenzepin can be increased when combined with Barbital.	Experimental
Diclofenamide	Barbital may increase the hypotensive activities of Diclofenamide.	Approved, Investigational
Dicoumarol	The metabolism of Dicoumarol can be increased when combined with Barbital.	Approved
Dienogest	The therapeutic efficacy of Dienogest can be decreased when used in combination with Barbital.	Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Barbital is combined with Diethyl ether.	Experimental
Diethylstilbestrol	The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbital.	Approved, Investigational
Difenoxin	The risk or severity of adverse effects can be increased when Difenoxin is combined with Barbital.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Barbital.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	Barbital may increase the hypotensive activities of Diltiazem.	Approved, Investigational
Dimenhydrinate	The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Barbital.	Approved
Dimetacrine	The metabolism of Dimetacrine can be increased when combined with Barbital.	Approved, Withdrawn
Dinutuximab	Barbital may increase the hypotensive activities of Dinutuximab.	Approved, Investigational
Diphenadione	The metabolism of Diphenadione can be increased when combined with Barbital.	Experimental
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital.	Approved, Investigational
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital.	Approved, Illicit
Dipyridamole	Barbital may increase the hypotensive activities of Dipyridamole.	Approved
Dixyrazine	The risk or severity of adverse effects can be increased when Barbital is combined with Dixyrazine.	Experimental
Doramectin	The risk or severity of adverse effects can be increased when Barbital is combined with Doramectin.	Vet Approved
Dosulepin	The metabolism of Dosulepin can be increased when combined with Barbital.	Approved
Dotarizine	The metabolism of Dotarizine can be increased when combined with Barbital.	Investigational
Doxazosin	Barbital may increase the hypotensive activities of Doxazosin.	Approved
Doxepin	The metabolism of Doxepin can be increased when combined with Barbital.	Approved, Investigational
Doxycycline	The serum concentration of Doxycycline can be decreased when it is combined with Barbital.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Barbital is combined with DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved, Vet Approved
Drospirenone	The therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbital.	Approved
Drotebanol	The risk or severity of adverse effects can be increased when Barbital is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.	Approved
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Barbital.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Barbital is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Barbital is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Efavirenz is combined with Barbital.	Approved, Investigational
Efonidipine	Barbital may increase the hypotensive activities of Efonidipine.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Barbital is combined with Eltanolone.	Investigational
Emopamil	The metabolism of Emopamil can be increased when combined with Barbital.	Experimental
Empagliflozin	Barbital may increase the hypotensive activities of Empagliflozin.	Approved
Enalapril	Barbital may increase the hypotensive activities of Enalapril.	Approved, Vet Approved
Enalaprilat	Barbital may increase the hypotensive activities of Enalaprilat.	Approved
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Barbital.	Approved, Investigational, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Entacapone is combined with Barbital.	Approved, Investigational
Epanolol	The serum concentration of Epanolol can be decreased when it is combined with Barbital.	Experimental
Eperisone	The metabolism of Eperisone can be increased when combined with Barbital.	Approved, Investigational
Epitizide	Barbital may increase the orthostatic hypotensive activities of Epitizide.	Experimental
Eplerenone	Barbital may increase the hypotensive activities of Eplerenone.	Approved
Epoprostenol	Barbital may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	Barbital may increase the hypotensive activities of Eprosartan.	Approved
Esatenolol	The serum concentration of Esatenolol can be decreased when it is combined with Barbital.	Experimental
Escitalopram	The risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.	Approved, Investigational
Esmolol	The serum concentration of Esmolol can be decreased when it is combined with Barbital.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Barbital.	Approved, Illicit
Estradiol	The therapeutic efficacy of Estradiol can be decreased when used in combination with Barbital.	Approved, Investigational, Vet Approved
Estradiol cypionate	The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Barbital.	Approved, Investigational, Vet Approved
Estradiol valerate	The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Barbital.	Approved, Investigational, Vet Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital.	Approved, Investigational
Etacrynic acid	Barbital may increase the hypotensive activities of Etacrynic acid.	Approved, Investigational
Ethanol	Barbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbital.	Approved
Ethosuximide	The metabolism of Ethosuximide can be increased when combined with Barbital.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Ethotoin is combined with Barbital.	Approved
Ethyl biscoumacetate	The metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital.	Approved, Illicit
Ethynodiol diacetate	The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbital.	Approved
Etidocaine	The risk or severity of adverse effects can be increased when Barbital is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Barbital is combined with Etifoxine.	Investigational, Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Barbital is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.	Approved
Etonogestrel	The therapeutic efficacy of Etonogestrel can be decreased when used in combination with Barbital.	Approved, Investigational
Etoperidone	The risk or severity of adverse effects can be increased when Barbital is combined with Etoperidone.	Withdrawn
Etorphine	The risk or severity of adverse effects can be increased when Barbital is combined with Etorphine.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Ezogabine is combined with Barbital.	Approved, Investigational
Felbamate	The serum concentration of Barbital can be increased when it is combined with Felbamate.	Approved
Felodipine	Barbital may increase the hypotensive activities of Felodipine.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital.	Approved, Illicit, Withdrawn
Fendiline	The metabolism of Fendiline can be increased when combined with Barbital.	Withdrawn
Fenoldopam	Barbital may increase the hypotensive activities of Fenoldopam.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Fexofenadine is combined with Barbital.	Approved, Investigational
Fimasartan	Barbital may increase the hypotensive activities of Fimasartan.	Approved, Investigational
Fish oil	The metabolism of Fish oil can be increased when combined with Barbital.	Approved, Nutraceutical
Flibanserin	The risk or severity of adverse effects can be increased when Flibanserin is combined with Barbital.	Approved, Investigational
Fluanisone	The risk or severity of adverse effects can be increased when Barbital is combined with Fluanisone.	Experimental
Fludiazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam.	Approved, Illicit
Fluindione	The metabolism of Fluindione can be increased when combined with Barbital.	Approved, Investigational
Flunarizine	The metabolism of Flunarizine can be increased when combined with Barbital.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.	Approved, Investigational, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital.	Approved, Illicit, Investigational
Fluspirilene	The metabolism of Fluspirilene can be increased when combined with Barbital.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Barbital.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Barbital is combined with Fluvoxamine.	Approved, Investigational
Fosinopril	Barbital may increase the hypotensive activities of Fosinopril.	Approved
Fosphenytoin	The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Barbital.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Barbital is combined with Fospropofol.	Approved, Illicit, Investigational
Furosemide	Barbital may increase the hypotensive activities of Furosemide.	Approved, Vet Approved
Gabapentin	The metabolism of Gabapentin can be increased when combined with Barbital.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Barbital.	Approved, Investigational
Gallopamil	The metabolism of Gallopamil can be increased when combined with Barbital.	Investigational
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Barbital.	Approved, Illicit, Investigational
Ganciclovir	The serum concentration of Ganciclovir can be decreased when it is combined with Barbital.	Approved, Investigational
Gepirone	The risk or severity of adverse effects can be increased when Barbital is combined with Gepirone.	Investigational
Gestodene	The therapeutic efficacy of Gestodene can be decreased when used in combination with Barbital.	Approved, Investigational
Gestrinone	The therapeutic efficacy of Gestrinone can be decreased when used in combination with Barbital.	Approved
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Barbital.	Approved, Illicit
Griseofulvin	The serum concentration of Griseofulvin can be decreased when it is combined with Barbital.	Approved, Investigational, Vet Approved
Guanfacine	Barbital may increase the hypotensive activities of Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Barbital.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Barbital.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Barbital.	Approved, Illicit, Investigational
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital.	Approved
Hydralazine	Barbital may increase the hypotensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of hypotension and orthostatic hypotension can be increased when Barbital is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	Barbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	Barbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.	Approved, Investigational
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.	Approved, Illicit
Hydroxyprogesterone caproate	The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Barbital.	Approved, Investigational
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Barbital.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Iloperidone is combined with Barbital.	Approved
Iloprost	Barbital may increase the hypotensive activities of Iloprost.	Approved, Investigational
Imidapril	Barbital may increase the hypotensive activities of Imidapril.	Investigational
Imipramine	The metabolism of Imipramine can be increased when combined with Barbital.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.	Investigational, Withdrawn
Indapamide	Barbital may increase the orthostatic hypotensive activities of Indapamide.	Approved
Indenolol	The serum concentration of Indenolol can be decreased when it is combined with Barbital.	Withdrawn
Indiplon	The risk or severity of adverse effects can be increased when Barbital is combined with Indiplon.	Investigational
Indoramin	Barbital may increase the hypotensive activities of Indoramin.	Withdrawn
Ipratropium	The risk or severity of adverse effects can be increased when Ipratropium is combined with Barbital.	Approved
Iprindole	The metabolism of Iprindole can be increased when combined with Barbital.	Experimental
Irbesartan	Barbital may increase the hypotensive activities of Irbesartan.	Approved, Investigational
Isocarboxazid	Barbital may increase the hypotensive activities of Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Barbital.	Approved, Vet Approved
Isosorbide Dinitrate	Barbital may increase the hypotensive activities of Isosorbide Dinitrate.	Approved, Investigational
Isosorbide Mononitrate	Barbital may increase the hypotensive activities of Isosorbide Mononitrate.	Approved
Isoxsuprine	Barbital may increase the hypotensive activities of Isoxsuprine.	Approved, Withdrawn
Isradipine	Barbital may increase the hypotensive activities of Isradipine.	Approved, Investigational
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone.	Approved, Investigational
Labetalol	Barbital may increase the hypotensive activities of Labetalol.	Approved
Lacidipine	Barbital may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Barbital.	Approved, Investigational
Landiolol	The serum concentration of Landiolol can be decreased when it is combined with Barbital.	Investigational
Lercanidipine	Barbital may increase the hypotensive activities of Lercanidipine.	Approved, Investigational
Levetiracetam	The metabolism of Levetiracetam can be increased when combined with Barbital.	Approved, Investigational
Levobetaxolol	The serum concentration of Levobetaxolol can be decreased when it is combined with Barbital.	Approved, Investigational
Levobunolol	The serum concentration of Levobunolol can be decreased when it is combined with Barbital.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Barbital.	Approved, Investigational
Levocabastine	The risk or severity of adverse effects can be increased when Barbital is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of adverse effects can be increased when Levocetirizine is combined with Barbital.	Approved
Levodopa	Barbital may increase the hypotensive activities of Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital.	Approved, Investigational
Levomilnacipran	The risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran.	Approved, Investigational
Levonorgestrel	The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Barbital.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital.	Approved
Levosimendan	Barbital may increase the hypotensive activities of Levosimendan.	Approved, Investigational
Lidoflazine	The metabolism of Lidoflazine can be increased when combined with Barbital.	Experimental
Lisinopril	Barbital may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Lithium cation	The risk or severity of adverse effects can be increased when Lithium is combined with Barbital.	Experimental
Lofentanil	The risk or severity of adverse effects can be increased when Barbital is combined with Lofentanil.	Illicit
Lofepramine	The metabolism of Lofepramine can be increased when combined with Barbital.	Experimental
Lofexidine	The therapeutic efficacy of Barbital can be increased when used in combination with Lofexidine.	Approved, Investigational
Lomerizine	The metabolism of Lomerizine can be increased when combined with Barbital.	Experimental
Loperamide	The metabolism of Loperamide can be increased when combined with Barbital.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Barbital is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Loratadine is combined with Barbital.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Lormetazepam.	Approved
Losartan	Barbital may increase the hypotensive activities of Losartan.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Barbital.	Approved, Investigational
Lynestrenol	The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Barbital.	Approved, Investigational
Magnesium carbonate	The risk or severity of adverse effects can be increased when Barbital is combined with Magnesium carbonate.	Approved, Investigational
Magnesium citrate	The risk or severity of adverse effects can be increased when Barbital is combined with Magnesium citrate.	Approved
Magnesium hydroxide	The risk or severity of adverse effects can be increased when Barbital is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium sulfate	The therapeutic efficacy of Barbital can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Magnesium Trisilicate	The risk or severity of adverse effects can be increased when Barbital is combined with Magnesium Trisilicate.	Approved
Manidipine	The metabolism of Manidipine can be increased when combined with Barbital.	Approved, Investigational
Mannitol	Barbital may increase the hypotensive activities of Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Maprotiline is combined with Barbital.	Approved, Investigational
Mebicar	The risk or severity of adverse effects can be increased when Barbital is combined with Mebicar.	Experimental
Mecamylamine	Barbital may increase the hypotensive activities of Mecamylamine.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Meclizine is combined with Barbital.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Barbital is combined with Medetomidine.	Vet Approved
Medrogestone	The serum concentration of Medrogestone can be decreased when it is combined with Barbital.	Approved
Medroxyprogesterone acetate	The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbital.	Approved, Investigational
Megestrol acetate	The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Barbital.	Approved, Investigational, Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Barbital.	Approved, Nutraceutical, Vet Approved
Melitracen	The metabolism of Melitracen can be increased when combined with Barbital.	Experimental, Investigational
Melperone	The risk or severity of adverse effects can be increased when Barbital is combined with Melperone.	Approved, Investigational
Menthol	The metabolism of Menthol can be increased when combined with Barbital.	Approved
Mepindolol	The serum concentration of Mepindolol can be decreased when it is combined with Barbital.	Experimental
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Barbital is combined with Meptazinol.	Experimental
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.	Approved, Investigational
Mestranol	The therapeutic efficacy of Mestranol can be decreased when used in combination with Barbital.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Metaxalone is combined with Barbital.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Barbital.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Barbital.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Barbital is combined with Methaqualone.	Illicit, Withdrawn
Methazolamide	Barbital may increase the hypotensive activities of Methazolamide.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Methocarbamol is combined with Barbital.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Barbital.	Approved
Methotrimeprazine	Barbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital.	Approved, Investigational, Vet Approved
Methsuximide	The metabolism of Methsuximide can be increased when combined with Barbital.	Approved
Methyclothiazide	Barbital may increase the orthostatic hypotensive activities of Methyclothiazide.	Approved
Methyldopa	Barbital may increase the hypotensive activities of Methyldopa.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Barbital is combined with Methylecgonine.	Experimental
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.	Approved
Metipranolol	The serum concentration of Metipranolol can be decreased when it is combined with Barbital.	Approved
Metoclopramide	The therapeutic efficacy of Barbital can be decreased when used in combination with Metoclopramide.	Approved, Investigational
Metolazone	Barbital may increase the orthostatic hypotensive activities of Metolazone.	Approved
Metoprolol	Barbital may increase the hypotensive activities of Metoprolol.	Approved, Investigational
Metyrosine	Barbital may increase the sedative activities of Metyrosine.	Approved
Mianserin	Mianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved, Investigational
Mibefradil	The metabolism of Mibefradil can be increased when combined with Barbital.	Investigational, Withdrawn
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.	Approved, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Barbital is combined with Milnacipran.	Approved, Investigational
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved, Investigational
Minoxidil	Barbital may increase the hypotensive activities of Minoxidil.	Approved, Investigational
Mirtazapine	Barbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Moexipril	Barbital may increase the hypotensive activities of Moexipril.	Approved
Molindone	The risk or severity of adverse effects can be increased when Barbital is combined with Molindone.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Barbital.	Approved, Investigational
Moxonidine	Barbital may increase the hypotensive activities of Moxonidine.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be decreased when it is combined with Barbital.	Approved
Naftopidil	The metabolism of Naftopidil can be increased when combined with Barbital.	Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital.	Approved
Nebivolol	The serum concentration of Nebivolol can be decreased when it is combined with Barbital.	Approved, Investigational
Nefazodone	The risk or severity of adverse effects can be increased when Barbital is combined with Nefazodone.	Approved, Withdrawn
Neomycin	The risk or severity of adverse effects can be increased when Barbital is combined with Neomycin.	Approved, Vet Approved
Nesiritide	Barbital may increase the hypotensive activities of Nesiritide.	Approved, Investigational
Nicardipine	Barbital may increase the hypotensive activities of Nicardipine.	Approved, Investigational
Nifedipine	Barbital may increase the hypotensive activities of Nifedipine.	Approved
Niguldipine	The metabolism of Niguldipine can be increased when combined with Barbital.	Experimental
Niludipine	The metabolism of Niludipine can be increased when combined with Barbital.	Experimental
Nilvadipine	Barbital may increase the hypotensive activities of Nilvadipine.	Approved, Investigational
Nimesulide	The metabolism of Nimesulide can be increased when combined with Barbital.	Approved, Investigational, Withdrawn
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Barbital.	Approved, Investigational
Nisoldipine	Barbital may increase the hypotensive activities of Nisoldipine.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Barbital.	Approved
Nitrendipine	Barbital may increase the hypotensive activities of Nitrendipine.	Approved, Investigational
Nitric Oxide	Barbital may increase the hypotensive activities of Nitric Oxide.	Approved
Nitroglycerin	Barbital may increase the hypotensive activities of Nitroglycerin.	Approved, Investigational
Nitroprusside	Barbital may increase the hypotensive activities of Nitroprusside.	Approved, Investigational
Nitrous acid	Barbital may increase the hypotensive activities of Nitrous acid.	Approved, Investigational
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Barbital.	Approved, Vet Approved
Nomegestrol acetate	The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Barbital.	Approved, Investigational
Nordazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Nordazepam.	Approved
Norelgestromin	The therapeutic efficacy of Norelgestromin can be decreased when used in combination with Barbital.	Approved, Investigational
Norethisterone	The therapeutic efficacy of Norethisterone can be decreased when used in combination with Barbital.	Approved
Norethynodrel	The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Barbital.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Barbital is combined with Norflurane.	Approved, Investigational
Norgestimate	The therapeutic efficacy of Norgestimate can be decreased when used in combination with Barbital.	Approved, Investigational
Norgestrel	The therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbital.	Approved
Norgestrienone	The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Barbital.	Experimental
Normethadone	The risk or severity of adverse effects can be increased when Barbital is combined with Normethadone.	Approved, Illicit
Nortriptyline	The metabolism of Nortriptyline can be increased when combined with Barbital.	Approved
Nylidrin	The metabolism of Nylidrin can be increased when combined with Barbital.	Approved
Obinutuzumab	Barbital may increase the hypotensive activities of Obinutuzumab.	Approved, Investigational
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital.	Approved, Investigational
Olmesartan	Barbital may increase the hypotensive activities of Olmesartan.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Barbital.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital.	Approved
Opipramol	The metabolism of Opipramol can be increased when combined with Barbital.	Investigational
Opium	The risk or severity of adverse effects can be increased when Barbital is combined with Opium.	Approved, Illicit
Orphenadrine	Barbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.	Investigational
Otilonium	The metabolism of Otilonium can be increased when combined with Barbital.	Experimental, Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital.	Approved
Oxprenolol	The risk or severity of adverse effects can be increased when Barbital is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Barbital.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital.	Approved, Investigational, Vet Approved
Paclitaxel	Barbital may increase the hypotensive activities of Paclitaxel.	Approved, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.	Approved
Papaverine	Barbital may increase the hypotensive activities of Papaverine.	Approved, Investigational
Paraldehyde	Barbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Paromomycin	The risk or severity of adverse effects can be increased when Barbital is combined with Paromomycin.	Approved, Investigational
Paroxetine	The risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.	Approved, Investigational
Penbutolol	The serum concentration of Penbutolol can be decreased when it is combined with Barbital.	Approved, Investigational
Penfluridol	The metabolism of Penfluridol can be increased when combined with Barbital.	Experimental
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital.	Approved, Investigational, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved
Perazine	The risk or severity of adverse effects can be increased when Barbital is combined with Perazine.	Approved, Investigational
Perindopril	Barbital may increase the hypotensive activities of Perindopril.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Barbital is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.	Approved
Pethidine	Barbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Barbital is combined with Phenazocine.	Experimental
Phenelzine	Barbital may increase the hypotensive activities of Phenelzine.	Approved
Phenibut	The risk or severity of adverse effects can be increased when Barbital is combined with Phenibut.	Experimental
Phenindione	The metabolism of Phenindione can be increased when combined with Barbital.	Approved, Investigational
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital.	Approved, Investigational
Phenoperidine	The risk or severity of adverse effects can be increased when Barbital is combined with Phenoperidine.	Experimental
Phenoxybenzamine	Barbital may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Barbital is combined with Phenoxyethanol.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be increased when combined with Barbital.	Approved, Investigational
Phentolamine	Barbital may increase the hypotensive activities of Phentolamine.	Approved
Phenytoin	The risk or severity of adverse effects can be increased when Phenytoin is combined with Barbital.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Barbital.	Approved
Pinaverium	The metabolism of Pinaverium can be increased when combined with Barbital.	Approved
Pindolol	The serum concentration of Pindolol can be decreased when it is combined with Barbital.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone.	Approved, Investigational
Pipotiazine	The risk or severity of adverse effects can be increased when Pipotiazine is combined with Barbital.	Approved, Investigational
Piritramide	The risk or severity of adverse effects can be increased when Barbital is combined with Piritramide.	Approved, Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Pizotifen is combined with Barbital.	Approved
Platelet Activating Factor	The serum concentration of Platelet Activating Factor can be decreased when it is combined with Barbital.	Experimental
Polymyxin B Sulfate	The risk or severity of adverse effects can be increased when Barbital is combined with Polymyxin B Sulfate.	Approved, Vet Approved
Polythiazide	Barbital may increase the orthostatic hypotensive activities of Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Pomalidomide is combined with Barbital.	Approved
Practolol	The serum concentration of Practolol can be decreased when it is combined with Barbital.	Approved
Pramipexole	Barbital may increase the sedative activities of Pramipexole.	Approved, Investigational
Prazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Prazepam.	Approved, Illicit
Prazosin	Barbital may increase the hypotensive activities of Prazosin.	Approved
Pregabalin	The therapeutic efficacy of Barbital can be increased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Prenylamine	The metabolism of Prenylamine can be increased when combined with Barbital.	Withdrawn
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Barbital.	Approved
Primidone	The risk or severity of adverse effects can be increased when Primidone is combined with Barbital.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Barbital.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Barbital.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Promethazine is combined with Barbital.	Approved, Investigational
Propacetamol	The metabolism of Propacetamol can be increased when combined with Barbital.	Approved, Investigational
Propafenone	The serum concentration of Propafenone can be decreased when it is combined with Barbital.	Approved
Propanidid	The risk or severity of adverse effects can be increased when Barbital is combined with Propanidid.	Experimental
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Barbital.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Barbital is combined with Propoxycaine.	Approved
Propranolol	Barbital may increase the hypotensive activities of Propranolol.	Approved, Investigational
Protriptyline	The metabolism of Protriptyline can be increased when combined with Barbital.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Barbital is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Barbital is combined with PSD502.	Investigational
Pseudoephedrine	The risk or severity of adverse effects can be increased when Barbital is combined with Pseudoephedrine.	Approved
Pyrantel	The risk or severity of adverse effects can be increased when Barbital is combined with Pyrantel.	Approved, Vet Approved
Pyridoxine	The metabolism of Barbital can be increased when combined with Pyridoxine.	Approved, Investigational, Nutraceutical, Vet Approved
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Barbital.	Approved, Illicit
Quetiapine	Barbital may increase the hypotensive activities of Quetiapine.	Approved
Quinapril	Barbital may increase the hypotensive activities of Quinapril.	Approved, Investigational
Quinethazone	Barbital may increase the orthostatic hypotensive activities of Quinethazone.	Approved
Quingestanol	The therapeutic efficacy of Quingestanol can be decreased when used in combination with Barbital.	Experimental
Quinisocaine	The risk or severity of adverse effects can be increased when Barbital is combined with Quinisocaine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Barbital is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Ramelteon is combined with Barbital.	Approved, Investigational
Ramipril	Barbital may increase the hypotensive activities of Ramipril.	Approved
Rasagiline	Barbital may increase the hypotensive activities of Rasagiline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Barbital.	Approved, Investigational
Rifabutin	The metabolism of Barbital can be increased when combined with Rifabutin.	Approved, Investigational
Rifampicin	The metabolism of Barbital can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Barbital can be increased when combined with Rifapentine.	Approved, Investigational
Rifaximin	The metabolism of Barbital can be increased when combined with Rifaximin.	Approved, Investigational
Riociguat	Barbital may increase the hypotensive activities of Riociguat.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Barbital is combined with Ritanserin.	Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Barbital is combined with Rizatriptan.	Approved
Romifidine	The risk or severity of adverse effects can be increased when Barbital is combined with Romifidine.	Vet Approved
Ropinirole	Barbital may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital.	Approved
Rotigotine	Barbital may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Barbital.	Approved
Sacubitril	Barbital may increase the hypotensive activities of Sacubitril.	Approved
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Barbital.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Barbital.	Approved, Investigational
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.	Approved, Vet Approved
Selegiline	Barbital may increase the hypotensive activities of Selegiline.	Approved, Investigational, Vet Approved
Seletracetam	The metabolism of Seletracetam can be increased when combined with Barbital.	Investigational
Sepranolone	The risk or severity of adverse effects can be increased when Barbital is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Barbital is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Barbital is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved
Somatostatin	The risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital.	Approved, Investigational
Sotalol	The serum concentration of Sotalol can be decreased when it is combined with Barbital.	Approved
Spironolactone	Barbital may increase the hypotensive activities of Spironolactone.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Stiripentol is combined with Barbital.	Approved
Streptokinase	Barbital may increase the hypotensive activities of Streptokinase.	Approved, Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.	Approved, Investigational
Sultopride	The risk or severity of adverse effects can be increased when Barbital is combined with Sultopride.	Experimental
Sumatriptan	The risk or severity of adverse effects can be increased when Barbital is combined with Sumatriptan.	Approved, Investigational
Suvorexant	Barbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Talinolol	The serum concentration of Talinolol can be decreased when it is combined with Barbital.	Investigational
Tamsulosin	Barbital may increase the hypotensive activities of Tamsulosin.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Barbital is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Tasimelteon is combined with Barbital.	Approved, Investigational
Telmisartan	Barbital may increase the hypotensive activities of Telmisartan.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Barbital.	Approved, Investigational
Teniposide	The serum concentration of Teniposide can be decreased when it is combined with Barbital.	Approved
Terazosin	Barbital may increase the hypotensive activities of Terazosin.	Approved
Terbutaline	The serum concentration of Terbutaline can be decreased when it is combined with Barbital.	Approved
Terodiline	The metabolism of Terodiline can be increased when combined with Barbital.	Experimental
Tertatolol	The serum concentration of Tertatolol can be decreased when it is combined with Barbital.	Experimental
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Barbital.	Approved, Investigational
Tetracaine	The risk or severity of adverse effects can be increased when Barbital is combined with Tetracaine.	Approved, Vet Approved
Tetracycline	The risk or severity of adverse effects can be increased when Barbital is combined with Tetracycline.	Approved, Vet Approved
Tetrahydropalmatine	The metabolism of Tetrahydropalmatine can be increased when combined with Barbital.	Investigational
Tetrandrine	The metabolism of Tetrandrine can be increased when combined with Barbital.	Experimental
Tetrodotoxin	The risk or severity of adverse effects can be increased when Barbital is combined with Tetrodotoxin.	Investigational
Thalidomide	Barbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Barbital.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Barbital.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital.	Approved, Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Barbital.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Tiagabine is combined with Barbital.	Approved, Investigational
Tianeptine	The metabolism of Tianeptine can be increased when combined with Barbital.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Barbital is combined with Tiapride.	Approved, Investigational
Tiletamine	The risk or severity of adverse effects can be increased when Barbital is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Barbital is combined with Tilidine.	Experimental
Timolol	The serum concentration of Timolol can be decreased when it is combined with Barbital.	Approved
Tioclomarol	The metabolism of Tioclomarol can be increased when combined with Barbital.	Experimental
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital.	Approved, Investigational
Tolazoline	Barbital may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolcapone	Barbital may increase the hypotensive activities of Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	The metabolism of Tolfenamic Acid can be increased when combined with Barbital.	Approved, Investigational
Topiramate	The risk or severity of adverse effects can be increased when Topiramate is combined with Barbital.	Approved
Torasemide	Barbital may increase the hypotensive activities of Torasemide.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.	Approved, Investigational
Trandolapril	Barbital may increase the hypotensive activities of Trandolapril.	Approved
Tranilast	The metabolism of Tranilast can be increased when combined with Barbital.	Approved, Investigational
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Barbital.	Approved, Investigational
Tretinoin	Barbital may increase the hypotensive activities of Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	Barbital may increase the hypotensive activities of Triamterene.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Barbital.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Barbital is combined with Tricaine methanesulfonate.	Vet Approved
Trichlormethiazide	Barbital may increase the orthostatic hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Barbital is combined with Trichloroethylene.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Barbital is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.	Approved, Vet Approved
Trimebutine	The metabolism of Trimebutine can be increased when combined with Barbital.	Approved
Trimethadione	The metabolism of Trimethadione can be increased when combined with Barbital.	Approved
Trimipramine	The metabolism of Trimipramine can be increased when combined with Barbital.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Triprolidine is combined with Barbital.	Approved
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Barbital.	Approved
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Barbital.	Approved
Ulipristal	The therapeutic efficacy of Ulipristal can be decreased when used in combination with Barbital.	Approved
Valaciclovir	The serum concentration of Valaciclovir can be decreased when it is combined with Barbital.	Approved, Investigational
Valproic Acid	The serum concentration of Barbital can be increased when it is combined with Valproic Acid.	Approved, Investigational
Valsartan	Barbital may increase the hypotensive activities of Valsartan.	Approved, Investigational
Vancomycin	The risk or severity of adverse effects can be increased when Barbital is combined with Vancomycin.	Approved
Vecuronium	The risk or severity of adverse effects can be increased when Barbital is combined with Vecuronium.	Approved
Venlafaxine	The risk or severity of adverse effects can be increased when Barbital is combined with Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Barbital is combined with Veralipride.	Experimental
Verapamil	Barbital may increase the hypotensive activities of Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Vigabatrin is combined with Barbital.	Approved
Vinpocetine	The metabolism of Vinpocetine can be increased when combined with Barbital.	Investigational
Vinyl ether	The risk or severity of adverse effects can be increased when Barbital is combined with Vinyl ether.	Experimental
Voriconazole	The serum concentration of Voriconazole can be decreased when it is combined with Barbital.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine.	Approved, Investigational
Warfarin	The metabolism of Warfarin can be increased when combined with Barbital.	Approved
WIN 55212-2	The metabolism of WIN 55212-2 can be increased when combined with Barbital.	Experimental
Xenon	The risk or severity of adverse effects can be increased when Barbital is combined with Xenon.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Barbital is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.	Approved, Illicit, Investigational
Ziconotide	The metabolism of Ziconotide can be increased when combined with Barbital.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Barbital is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Barbital is combined with Zolmitriptan.	Approved, Investigational
Zolpidem	Barbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The metabolism of Zonisamide can be increased when combined with Barbital.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Barbital.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Barbital is combined with Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Barbital.	Approved, Investigational

Food Interactions

Not Available

References

General References

Not Available

External Links

KEGG Compound

C02517

PubChem Compound

2294

PubChem Substance

46508979

ChemSpider

2206

ChEBI

31252

ChEMBL

CHEMBL444

Therapeutic Targets Database

DAP001350

PharmGKB

PA448538

Wikipedia

Barbital

ATC Codes

N05CA04 — Barbital

• N05CA — Barbiturates, plain
• N05C — HYPNOTICS AND SEDATIVES
• N05 — PSYCHOLEPTICS
• N — NERVOUS SYSTEM

Clinical Trials

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	190 °C	PhysProp
boiling point (°C)	250 °C at 2.20E+01 mm Hg	PhysProp
water solubility	7460 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	0.65	HANSCH,C ET AL. (1995)
logS	-1.39	ADME Research, USCD
pKa	8.14 (at 15 °C)	KORTUM,G ET AL (1961)

Predicted Properties

Property	Value	Source
Water Solubility	3.23 mg/mL	ALOGPS
logP	0.73	ALOGPS
logP	0.72	ChemAxon
logS	-1.8	ALOGPS
pKa (Strongest Acidic)	8.48	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	75.27 Å2	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	44.25 m3·mol-1	ChemAxon
Polarizability	17.59 Å3	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.955
Blood Brain Barrier	+	0.9694
Caco-2 permeable	-	0.6146
P-glycoprotein substrate	Non-substrate	0.5238
P-glycoprotein inhibitor I	Non-inhibitor	0.7826
P-glycoprotein inhibitor II	Non-inhibitor	0.9964
Renal organic cation transporter	Non-inhibitor	0.9395
CYP450 2C9 substrate	Non-substrate	0.7915
CYP450 2D6 substrate	Non-substrate	0.9074
CYP450 3A4 substrate	Non-substrate	0.7823
CYP450 1A2 substrate	Non-inhibitor	0.896
CYP450 2C9 inhibitor	Non-inhibitor	0.9436
CYP450 2D6 inhibitor	Non-inhibitor	0.9586
CYP450 2C19 inhibitor	Non-inhibitor	0.918
CYP450 3A4 inhibitor	Non-inhibitor	0.9723
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9847
Ames test	AMES toxic	0.5531
Carcinogenicity	Non-carcinogens	0.8532
Biodegradation	Not ready biodegradable	0.9462
Rat acute toxicity	3.5489 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9913
hERG inhibition (predictor II)	Non-inhibitor	0.9734

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (8.31 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
GC-MS Spectrum - CI-B	GC-MS	splash10-000i-0900000000-90fb45d882d2c3ed038f
GC-MS Spectrum - EI-B	GC-MS	splash10-052f-9400000000-fa1289872f9f35015abc
GC-MS Spectrum - EI-B	GC-MS	splash10-052f-9500000000-856a7fe5dbfd28d00c38
GC-MS Spectrum - EI-B	GC-MS	splash10-0a4l-2900000000-42c0874d0bac13cc2d94
GC-MS Spectrum - EI-B	GC-MS	splash10-0a4u-5900000000-497f9ee367181a6df30a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Diazines

Sub Class

Pyrimidines and pyrimidine derivatives

Direct Parent

Barbituric acid derivatives

Alternative Parents

N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

Substituents

Barbiturate / N-acyl urea / Ureide / 1,3-diazinane / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative / Azacycle / Organic nitrogen compound

Molecular Framework

Aliphatic heteromonocyclic compounds

External Descriptors

barbiturates (CHEBI:31252)

Drug created on July 31, 2007 07:09 / Updated on August 02, 2018 04:36